Legal compliance attestations.

Retatrutide attestation

LegitPep does not offer retatrutide to patients. LegitPep and LegitPep's partner medical providers do not prescribe or offer the unapproved drug retatrutide through the LegitPep platform.

Discontinued peptide offerings

LegitPep has removed patient-facing offers for the following peptide therapies from the website: BPC-157, TB-500, injectable GHK-Cu, KPV, CJC-1295, Ipamorelin, Tesamorelin, MOTS-c, Semax, and Selank.

Current medical practitioner network

LegitPep's current medical practitioner network partner for telehealth services is LocumTele. LegitPep does not publish a separate public roster of individual clinicians because treating-provider assignment depends on the patient's state, eligibility, and availability. Before a consultation is completed, each patient receives the name, professional credentials, and license information for the treating provider assigned to that patient's care.

• Network partner: LocumTele
• Provider type: Independent US-licensed healthcare providers
• Patient disclosure: Treating provider name, credentials, and license details are disclosed before completion of care and remain available in the patient portal.

Contact

For compliance, legal, or provider-network documentation requests, contact privacy@legitpep.com.